Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Position Decreased by Voya Investment Management LLC

Voya Investment Management LLC lowered its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 6.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,488 shares of the company’s stock after selling 3,442 shares during the period. Voya Investment Management LLC’s holdings in Amneal Pharmaceuticals were worth $384,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMRX. Price T Rowe Associates Inc. MD boosted its stake in Amneal Pharmaceuticals by 11.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 97,250 shares of the company’s stock worth $771,000 after purchasing an additional 9,704 shares during the period. BlackBarn Capital Partners LP boosted its position in shares of Amneal Pharmaceuticals by 18.2% in the fourth quarter. BlackBarn Capital Partners LP now owns 2,850,000 shares of the company’s stock worth $22,572,000 after buying an additional 438,388 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Amneal Pharmaceuticals by 29.7% during the fourth quarter. Hsbc Holdings PLC now owns 60,061 shares of the company’s stock valued at $476,000 after buying an additional 13,757 shares in the last quarter. MetLife Investment Management LLC raised its position in Amneal Pharmaceuticals by 2.5% during the fourth quarter. MetLife Investment Management LLC now owns 94,639 shares of the company’s stock valued at $750,000 after buying an additional 2,297 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Amneal Pharmaceuticals by 5.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company’s stock worth $39,531,000 after acquiring an additional 278,653 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Price Performance

Amneal Pharmaceuticals stock opened at $7.42 on Friday. Amneal Pharmaceuticals, Inc. has a one year low of $6.29 and a one year high of $9.48. The company’s fifty day moving average price is $7.90 and its two-hundred day moving average price is $8.13. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of -10.91 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.05. The business had revenue of $695.42 million for the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. As a group, sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at $405,628,045.15. This represents a 9.33 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total value of $712,000.00. Following the completion of the transaction, the director now directly owns 1,808,886 shares in the company, valued at approximately $16,099,085.40. This represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on AMRX shares. Barclays raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday, March 3rd. StockNews.com upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, May 5th. Finally, JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $11.50.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.